Nucleic acid therapies involving DNA or RNA have significant potential to treat genetic disorders, infectious diseases, and cancer; however, research suggests that less than 1% of injected nucleic acid doses reach target cells in an active form. An article in WIREs Nanomedicine and Nanobiotechnology highlights two of the major barriers to this therapeutic strategy, and how they might be overcome.
Delivery to the target cell and transport to the sub-cellular compartment where the nucleic acids are therapeutically active represent the most significant challenges to address. The authors explore how nanoparticle delivery systems can be modified with targeting molecules to increase accumulation in specific cells, and how the composition of the nanoparticle can be engineered to manipulate or disrupt cellular membranes and facilitate delivery to the optimal sub-cellular compartments.
“Controlling the sub-cellular delivery of DNA and RNA is the next major frontier for biotherapeutics. If we can overcome these barriers, DNA and RNA technology has the potential to revolutionize the treatment of a range of diseases,” said corresponding author Angus P.R. Johnston, Ph.D., of Monash University, in Australia.
Lara M. Mollé et al, Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery, WIREs Nanomedicine and Nanobiotechnology (2022). DOI: 10.1002/wnan.1809
Overcoming challenges in the delivery of nucleic acid therapeutics (2022, November 23)
retrieved 23 November 2022
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.